Niacin/simvastatin compared to simvastatin alone at 2 doses
ApprovedCompleted 1 views this week 0 watching⚡ Active
Interest: 43/100
43
Development Stage
✓
Pre-clinical✓
Phase 1✓
Phase 2✓
Phase 35
ApprovedIndication / Disease
Established Carotid Atherosclerosis
Conditions
Established Carotid Atherosclerosis
Trial Timeline
Jan 1, 2000 → Sep 1, 2005
NCT ID
NCT00307307About Niacin/simvastatin compared to simvastatin alone at 2 doses
Niacin/simvastatin compared to simvastatin alone at 2 doses is a approved stage product being developed by Merck for Established Carotid Atherosclerosis. The current trial status is completed. This product is registered under clinical trial identifier NCT00307307. Target conditions include Established Carotid Atherosclerosis.
What happened to similar drugs?
0 of 1 similar drugs in Established Carotid Atherosclerosis were approved
Approved (0) Terminated (0) Active (1)
Hype Score Breakdown
Clinical
20
Activity
8
Company
15
Novelty
0
Community
0
Clinical Trials (1)
| NCT ID | Phase | Status |
|---|---|---|
| NCT00307307 | Approved | Completed |
Competing Products
2 competing products in Established Carotid Atherosclerosis
| Product | Company | Stage | Hype Score |
|---|---|---|---|
| TQJ230 + Placebo | Novartis | Phase 3 | 44 |
| NNC0385-0434 | Novo Nordisk | Phase 1 | 29 |